Company intelligence / Profile preview

Heyuan Biotechnology

Ownership: Private
Development stage: Commercial

Overview

Heyuan Biotech's CD19-targeted CAR-T cell therapy drug product...approved for marketing...for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia. This is China's first CAR-T therapy for this indication... Plant-derived products have entered clinical trials; details on efficacy/safety not specified in public sources.

Therapeutic areas: OncologyHematology
Modalities: CAR-T cell therapyRecombinant proteinSmall molecule polypeptide
Industry: Biotech

Drug pipeline

1 asset

CNCT19

Commercial

Indications: B-cell acute lymphoblastic leukemia

Partnerships

Liji Biotechnology

Beyond the preview

Go deeper on Heyuan Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heyuan Biotechnology.

Explore the full profile